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The E3 ubiquitin ligase Trim7 mediates c-Jun/AP-1
activation by Ras signalling
Atanu Chakraborty1, Markus E. Diefenbacher1, Anastasia Mylona2, Olivier Kassel3 & Axel Behrens1,4
The c-Jun/AP-1 transcription factor controls key cellular behaviours, including proliferation
and apoptosis, in response to JNK and Ras/MAPK signalling. While the JNK pathway has
been well characterized, the mechanism of activation by Ras was elusive. Here we identify the
uncharacterized ubiquitin ligase Trim7 as a critical component of AP-1 activation via Ras.
We found that MSK1 directly phosphorylates Trim7 in response to direct activation by the
Ras–Raf–MEK–ERK pathway, and this modification stimulates Trim7 E3 ubiquitin ligase
activity. Trim7 mediates Lys63-linked ubiquitination of the AP-1 co-activator RACO-1, leading
to RACO-1 protein stabilization. Consequently, Trim7 depletion reduces RACO-1 levels and
AP-1-dependent gene expression. Moreover, transgenic overexpression of Trim7 increases
lung tumour burden in a Ras-driven cancer model, and knockdown of Trim7 in established
xenografts reduces tumour growth. Thus, phosphorylation–ubiquitination crosstalk between
MSK1, Trim7 and RACO-1 completes the long sought-after mechanism linking growth factor
signalling and AP-1 activation.
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T
he Ras signalling pathway regulates a large and diverse
array of cellular decisions, including cell proliferation.
Around 30% of all human tumours harbour activating
mutations in Ras or its downstream kinases, which contribute
towards several aspects of the malignant phenotype such as
deregulated growth, apoptosis and invasiveness1–3. Oncogenic
Ras induces constitutive activation of many effectors that are
normally activated by growth factor stimulation, driving cell
growth and proliferation1. Among these effects is the
upregulation of c-Jun, a member of the AP-1 transcriptional
activator family, which controls transcription of cell cycle
regulator genes including cyclinD1 and cdc2 (refs 4–7). In line
with this, c-Jun / mouse embryonic fibroblasts display severe
proliferation defects and deficiency in cell cycle re-entry after
serum withdrawal4,8,9. c-Jun also has been demonstrated to be
crucial for Ras-driven transformation, as c-Jun knockout mouse
embryonic fibroblasts were refractory to the effects of oncogenic
Ras10. c-Jun responds to growth factor stimulation via extra-
cellular signal-regulated kinase (ERK) as well as cellular stress via
the JNK pathway, and mediates diverse cellular responses ranging
from proliferation, migration and differentiation to tumorigenesis
and cellular apoptosis4,11,12. The activation of c-Jun via JNK has
been well characterized13,14; however, the molecular mechanism
connecting c-Jun and active Ras–Raf–MEK–ERK signalling,
potentially crucial to its role in tumourigenesis, remains
incomplete.
We previously described a novel c-Jun co-activator, RING
domain AP-1 co-activator 1 (RACO-1), a RING domain-
containing E3 ubiquitin ligase, which is stabilized by growth
factor signalling. RACO-1 stability is regulated by a ubiquitin
switch between Lys48 (K48)- and Lys63 (K63)-linked ubiquitina-
tion, controlled by active MEK15 and by PRMT1-mediated
arginine methylation16. Methylation of two arginine residues in
the N terminus of RACO-1 (R98, 109) stabilizes RACO-1 in a
dimeric conformation and is a prerequisite for all known RACO-
1 functions16.
RACO-1 depletion reduces cellular proliferation and down-
regulates several growth-associated AP-1 target genes, such as
cdc2, cyclinD1 and hb–egf. On the other hand, transgenic
overexpression of RACO-1 augments intestinal tumour forma-
tion triggered by aberrant Wnt signalling and cooperates with
oncogenic Ras in colon epithelial hyperproliferation15. These data
indicate that RACO-1 forms part of the link between Ras and
c-Jun in tumourigenesis. However, the molecular players
inducing the ubiquitin switch downstream of MEK to stabilize
RACO-1 were not known.
In this study, we identify a previously uncharacterized
ubiquitin ligase, Tripartite Motif-containing 7 (Trim7), which
on Ras–Raf–MEK–ERK pathway activation, is phosphorylated
and activated by MSK1. Trim7 in turn ubiquitinates and stabilizes
RACO-1, leading to increased c-Jun transcription. These findings
delineate the complete pathway by which growth factor signalling
stimulates c-Jun function, and provide further evidence for the
importance of phosphorylation–ubiquitination crosstalk in fun-
damental aspects of cell signalling. Underlining the importance of
this pathway in vivo, we find that Trim7 cooperates with
oncogenic Ras to drive lung tumorigenesis.
Results
Identification of Trim7 as a RACO-1 interacting protein. The
c-Jun co-activator RACO-1 is stabilized by growth factor sig-
nalling via MEK, and is therefore a component of the unchar-
acterized pathway linking Ras signalling with c-Jun/AP-1
transcription15. To identify other components of this pathway, we
used a biotinylated peptide (163–235) corresponding to the
RACO-1 C terminus, encompassing the ubiquitinated residues
K195, K223 and K224, in order to find protein interactors likely
to affect RACO-1 stability (Fig. 1a). RACO-1 (163–235) or the
scrambled peptide was incubated with HeLa cell extract, followed
by affinity-capture using streptavidin beads. Using mass
spectrometry, we identified a previously uncharacterized
ubiquitin ligase, Trim7, interacting with RACO-1. The TRIM
family of proteins is identified by tripartite motifs, which consist
of a RING domain, followed by a B-Box and a coiled-coil domain.
The C-terminal end varies between family members and, in the
case of Trim7, contains a C-terminal B30.2 (SPRY) domain17
(Fig. 1a). Flag-tagged RACO-1 co-immunoprecipitated with Myc-
tagged Trim7, confirming the interaction (Fig. 1b). Fine mapping
with different deletion constructs encompassing RACO-1 showed
that Trim7 interacts specifically with the very C terminus of
RACO-1 (Supplementary Fig. 1a,b).
Next, we investigated the effect of Trim7 on RACO-1 stability.
RACO-1 protein is highly unstable in unstimulated conditions,
since it is subject to autoubiquitination with K48-linked
ubiquitin via its own RING domain and degradation by the
proteasome15. However, overexpression of Myc–Trim7 in 293T
cells greatly increased RACO-1 protein levels (Fig. 1c).
Conversely, knocking down Trim7 decreased levels of
endogenous RACO-1 in the H727 human lung adenocarcinoma
cell line. This decrease occurred through proteasome-mediated
degradation, as inhibiting the proteasome restored RACO-1
protein levels (Fig. 1d). Similar results were obtained with
ectopically expressed FLAG-tagged RACO-1, and with two
independent trim7 siRNAs (Fig. 1e and Supplementary
Fig. 1c). Moreover, Trim7 knockdown in H727 cells had no
significant effect on RACO-1 mRNA measured by quantitative
reverse transcription–PCR (qRT–PCR; Supplementary Fig. 1d),
excluding an effect of Trim7 on RACO-1 transcription. To
determine whether Trim7 affects RACO-1 protein stability, we
performed a time course experiment to monitor FLAG–RACO-1
degradation in the presence of cycloheximide to inhibit protein
synthesis. Overexpression of Myc–Trim7 significantly slowed the
degradation of RACO-1 (Fig. 1f,g), while knockdown of Trim7
accelerated degradation of the protein (Supplementary Fig. 1e,f).
Together with the results above, these findings demonstrate that
Trim7 stabilizes the RACO-1 protein.
Our previous results showed that RACO-1 stability is regulated
by MEK–ERK signalling, and the effect of RACO-1 on c-Jun is
independent of JNK phosphorylation15. In line with this,
stimulation of JNK by anisomycin does not increase RACO-1
levels (Supplementary Fig. 1g). To test whether Trim7-mediated
stabilization of RACO-1 is under the control of the MEK–ERK
pathway, Trim7 was knocked down by short hairpin RNA
(shRNA) and the cells were treated with phorbol ester (12-O-
tetradecanoyl phorbol 13-acetate, TPA), which activates the
MEK–ERK pathway. TPA treatment increased RACO-1 protein
levels, but failed to do so in Trim7-depleted samples (Fig. 1h). As
TPA is known to activate other signalling pathways in addition to
MEK–ERK signalling, we used a constitutively active MEK1
(MEKR4F) to activate the MEK–ERK pathway specifically.
MEKR4F increased RACO-1 protein levels in control cells;
however, this effect was significantly reduced when Trim7 was
knocked down (Fig. 1i). These results imply that RACO-1
stabilization by MEK–ERK signalling requires Trim7.
Trim7 directly ubiquitinates RACO-1 using K63-linked chains.
To investigate the mechanistic basis of RACO-1 stabilization by
Trim7, 293T cells were transfected with His-ubiquitin and
RACO-1 with or without Trim7. In vivo ubiquitination assay
using Ni2þ -NTA pulldown of ubiquitinated proteins showed
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that Trim7 stimulates RACO-1 ubiquitination (Fig. 2a). Next, we
used two ubiquitin mutants, K48R and K63R, to identify the
chain linkage of ubiquitinated RACO-1. Trim7 stimulated effi-
cient ubiquitination of RACO-1 using K48R ubiquitin; however,
ubiquitination was significantly reduced when K63R-mutant
ubiquitin was used. Thus, Trim7 promotes RACO-1 ubiquitina-
tion with K63-linked ubiquitin chains (Fig. 2b). Trim7 is pre-
dicted to be a ubiquitin ligase, as it contains a RING domain;
however, this has not been experimentally validated. To test
whether the RING domain of Trim7 is important for RACO-1
ubiquitination, we mutated Cys29 and Cys32 to alanine
(C29,32A), which destroys the integrity of the RING domain. In
addition, we mutated a conserved tryptophan residue (Trp57) to
alanine (W57A), which is important for the interaction of the
RING domain with ubiquitin-conjugating enzymes (E2s)18. Both
the mutant Trim7 proteins failed to stabilize RACO-1 (Fig. 2c). In
vivo ubiquitination assay using wild-type (WT) or RING mutant
Trim7 also demonstrated the inability of the Trim7 mutants to
ubiquitinate RACO-1 (Fig. 2d). Interestingly, overexpression of
mutant Trim7 reduced FLAG–RACO-1 protein below control
levels (Fig. 2c), suggesting that the mutant has a dominant-
negative effect over the endogenous Trim7. In support of this
idea, FLAG-tagged Trim7 was able to pull down Myc-tagged
Trim7 by co-immunoprecipitation (Supplementary Fig. 2a),
suggesting that, in common with other RING E3 ligases, Trim7
may act as a homodimer.
Previously, we have shown that active RACO-1 is a homodimer
and PRMT1-mediated methylation of RACO-1 is a prerequisite
for efficient dimer formation16. In order to identify whether
Trim7 preferentially ubiquitinates dimeric RACO-1, we used a
mutant RACO-1 lacking two arginines that are targets for
PRMT1-mediated methylation (RACO-1 R98,109K) that is,
therefore, compromised in dimerization ability. Overexpression
of Trim7 did not stabilize RACO-1 R98,109K (Fig. 2e), and
in vivo ubiquitination assay revealed that Trim7 was unable to
stimulate ubiquitination of this mutant protein (Fig. 2f),
suggesting that dimeric RACO-1 is the optimal substrate for
Trim7.
Next, we wanted to test whether Trim7 directly ubiquitinates
RACO-1. Ectopically expressed FLAG–RACO-1 was immuno-
precipitated from 293T cells and was used as a substrate for
in vitro ubiquitination assay (Fig. 2g). Recombinant GST
(glutathione S-transferase)-tagged Trim7 ubiquitinated RACO-1
only when all the purified components of the ubiquitination
cascade (ubiquitin, ATP, E1, E2 and E3 ligases) were present.
Moreover, the C29,32A and W57A mutants of Trim7 did not
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Figure 1 | Trim7 regulates RACO-1 stability in a MEK-dependent manner. (a) Scheme of mass spectrometry experiment to identify RACO-1 interactors,
showing domain structures of RACO-1 and Trim7. RING (zinc finger), B-box, coiled-coil (CC) and SPRY (protein–protein interaction) domains are shown.
(b) FLAG–RACO-1 immunoprecipitation from cells transfected with Myc–Trim7 and blotted for Myc and FLAG. (c) Western blots showing the effect of
Myc–Trim7 overexpression on FLAG–RACO-1 levels. (d) Western blot showing the effect of Trim7 depletion on endogenous RACO-1 levels in human lung
H727 cells, in the presence and absence of proteasome inhibitor (MG132). Arrowhead indicates Trim7 band; asterisk indicates a nonspecific band.
(e) Western blots showing the effect of Trim7 depletion on FLAG–RACO-1 levels, in the presence and absence of MG132. (f) Western blots showing the
degradation of FLAG–RACO-1 over time in the presence of cycloheximide (CHX), in control cells and cells overexpressing Myc–Trim7. (g) Quantification
of f and two other similar CHX time course experiments showing RACO-1 stability. Error bars indicate s.e.m. P¼0.0086 (Student’s t-test comparing
RACO-1 levels at 240min). (h) Western blot showing RACO-1 levels in control and Trim7-depleted cells after treatment with dimethylsulphoxide (vehicle)
or TPA to stimulate MEK signalling. (i) Western blots showing the effect of Trim7 depletion by shRNA in the presence or absence of constitutively
active MEK (MEKR4F). Actin is shown as loading control. Experiments were replicated at least three times.
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ubiquitinate RACO-1 (Fig. 2g), implying that RACO-1 ubiqui-
tination requires a functional Trim7 RING domain. Taken
together, these data suggest that Trim7 directly ubiquitinates
RACO-1.
RACO-1 stabilization by MEK requires MSK1 activity. We next
investigated the mechanism of Trim7 regulation by growth factor
signalling. The requirement of Trim7 for RACO-1 stabilization by
MEKR4F (Fig. 1i) suggested that the Trim7-regulatory activity is
downstream of MEK. Knocking down ERK1/2 in 293T cells
reduced RACO-1 levels, suggesting that Trim7 is under the
control of ERK activity (Supplementary Fig. 2b). To test whether
ERK directly phosphorylates Trim7, we carried out an in vitro
kinase assay. Recombinant ERK efficiently phosphorylated Elk-1,
a canonical ERK substrate, but did not phosphorylate Trim7
(Supplementary Fig. 2c).
Mitogen and stress-activated protein kinase (MSK) and 90-kDa
ribosomal S6 kinase (RSK) kinases mediate signal transduction
downstream of MAPK signalling. Both the kinases are directly
phosphorylated and activated by ERK kinases19,20. In addition,
MSK1 has been shown to induce immediate early gene expression
on Ras activation, via the nucleosomal response21–23. We
therefore tested the effect of two MSK inhibitors, H-89 and Ro-
31–8220, as well as RSK inhibitor II, on RACO-1 stability
(Fig. 3a). Both MSK inhibitors destabilized RACO-1, while RSK
inhibitor II had no effect on RACO-1 protein levels, suggesting
that MSK is probably responsible for transducing the signals from
active MEK–ERK signalling towards RACO-1 (Fig. 3b). The
destabilization of RACO-1 by Ro-31–8220 was proteasome-
dependent, as adding proteasome inhibitor reverted this effect
(Fig. 3c). Inhibition of the MEK–ERK pathway in H727 cells with
the MEK inhibitor U0126 and the MSK inhibitor Ro-31–8220
decreased endogenous RACO-1 protein levels to a similar extent
(Fig. 3d).
The MSK protein kinase family consists of two members,
MSK1 and MSK2. To determine whether MSK1 or MSK2 is
responsible for RACO-1 stabilization, we depleted each of these
proteins individually by siRNA. Depletion of MSK1, but not
MSK2, reduced endogenous RACO-1 protein levels, and this
effect was rescued by proteasome inhibitor, suggesting that MSK1
is required for the stabilization of endogenous RACO-1 (Fig. 3e,f).
In support of this, overexpression of WT MSK1 increased
RACO-1 protein levels, but a catalytically dead MSK1 protein
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Figure 2 | Trim7 ubiquitinates RACO-1 through K63 linkage. (a) Ubiquitin pulldown using Ni2þ -NTA resin to precipitate ubiquitinated proteins from cells
transfected with FLAG–RACO-1 and Myc–Trim7 as indicated. (b) Ubiquitin pulldown as above using K48R or K63R-mutant ubiquitin, which cannot form
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(MSK1 D565A (ref. 20)) did not (Fig. 3g). In vivo ubiquitination
assay also confirmed this conclusion, as overexpression of WT
MSK1 increased RACO-1 ubiquitination, while MSK1 D565A
had no effect (Fig. 3h). MSK1 was required for RACO-1 protein
stabilization by TPA (Fig. 3i). Similarly, MSK1 was also required
for efficient RACO-1 stabilization by Trim7 overexpression,
suggesting that RACO-1 stabilization by MEK–ERK signalling
requires MSK1 (Fig. 3j).
MSK1 directly phosphorylates Trim7. To investigate the
mechanism of MSK1-mediated signal transduction resulting in
RACO-1 stabilization, we tested whether MSK1 directly phos-
phorylates Trim7. Wild-type MSK1 and the kinase-dead MSK1
D565A mutant were overexpressed in 293T cells, immunopreci-
pitated, and used for in vitro kinase assay using radioactive g32P-
ATP. Wild-type MSK1 specifically phosphorylated recombinant
GST–Trim7, while MSK1 D565A did not, suggesting that MSK1
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Experiments were replicated at least three times.
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directly phosphorylates Trim7 (Fig. 4a). MSK kinases phos-
phorylate serine residues within the consensus sequence
R/KxRxxS or RRxS. Analysis of the Trim7 amino-acid sequence
revealed a consensus phosphorylation site, Ser107, for the MSK
kinases (Supplementary Fig. 2d). Mutation of the S107 site on
Trim7 abolished this phosphorylation (Fig. 4b), confirming S107
as the MSK1 phosphorylation site on Trim7.
We generated an antibody specifically recognizing phosphory-
lated serine 107 of Trim7 to further investigate Trim7 regulation.
The pS107–Trim7 antibody detected Trim7 phosphorylated
with WT MSK1, but not the unphosphorylated Trim7,
demonstrating the specificity of the antibody (Fig. 4c). Ectopic
MSK1 expression increased Trim7 phosphorylation at S107,
validating that this modification occurs in vivo (Fig. 4d).
Mutation of Trim7 S107 to alanine inhibited the stabilization of
RACO-1, suggesting that phosphorylation of this site is required
for stimulation of Trim7 activity (Fig. 4e). Consistent with this,
Trim7 S107A was less able to ubiquitinate RACO-1 (Fig. 4f). To
determine whether phosphorylation of Trim7 S107A affected its
interaction with RACO-1, we performed co-immunoprecipitation
experiments. Neither activation nor inhibition of MEK signalling
(by TPA or U0126, respectively) nor mutation of the S107
phosphorylation site on Trim7 affected its interaction with
RACO-1 (Supplementary Fig. 3a,b), suggesting that MEK-
induced phosphorylation of Trim7 promotes its E3 ligase activity
by increasing the efficiency of ubiquitin transfer rather than
enhancing the interaction with RACO-1. Taken together, our data
suggest that on activation of the Ras–Raf–MEK–ERK pathway,
MSK1 phosphorylates Trim7 on serine 107 and stimulates its E3
ligase activity towards RACO-1, resulting in RACO-1
stabilization.
Trim7 promotes oncogenic Ras-mediated lung adenocarcinoma.
Adenocarcinoma, a form of non-small cell lung cancer, is the most
common type of lung cancer in humans. K-Ras mutations are
commonly found in non-small cell lung cancers and are believed
to play a key role in this malignancy. Data from The Cancer
Genome Atlas indicate that Trim7 is altered in 5% of human
lung adenocarcinomas, most frequently by overexpression
(Supplementary Fig. 4a). Moreover, amplified or overexpressed
RACO-1, present in 8% of these tumours, does not overlap with
Trim7 alteration, and there is also a tendency towards mutual
exclusivity with K-Ras mutations (Supplementary Fig. 4a)24,25, in
support of K-Ras, Trim7 and RACO-1 being in the same pathway.
Thus, we used a Ras-driven lung cancer model26,27 to test the
significance of the Trim7/RACO-1 axis in tumourigenesis. In this
mouse model, Cre-mediated recombination induces the expression
of oncogenic K-RasG12D (ref. 27). The transgene expression was
activated in the lung by tracheal intubation of mice with Cre-
expressing adenovirus (Adeno-Cre)26.
For transgenic overexpression of Trim7, we targeted a Cre-
inducible human Trim7 transgene to the Rosa26 locus. The
expression of the transgene is dependent on Cre recombinase-
mediated excision of a STOP cassette (Rosa26-loxSTOPlox-
Trim7-IRES-GFP or R26Trim7). The ‘KT ’ model combined
inducible K-RasG12D expression with transgenic Trim7 and green
fluorescent protein (GFP) expression from the Rosa26 promoter
(LSL-K-RasG12D; R26-LSL-Trim7-IRES-GFP; plus Adeno-Cre;
Fig. 5a). Total lung extracts from either K-RasG12D or KT mice
were used to isolate RNA and protein. Quantitative RT–PCR
showed the expression of the Trim7 transgene in the lungs of KT
mice (Fig. 5b). Western blot analysis of the proteins showed a
significant stabilization of RACO-1 in KT mice compared with
K-RasG12D mice (Fig. 5c).
As expected, expression of oncogenic K-RasG12D alone resulted
in formation of hyperplastic lesions and adenomas in the lungs
that stain positive for TTF-1 (Fig. 5d). TTF-1 is frequently
overexpressed in lung adenocarcinoma, and routinely used as a
marker for these tumours28,29. Quantification of the TTF-1-
positive transformed area of the lungs from K-RasG12D and KT
mice showed a significant increase in tumour burden in KT mice
(Fig. 5d,e), whereas transgenic overexpression of Trim7 alone did
not result in any TTF-1-positive lesions (Fig. 5e).
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Detailed analysis of the tumours was carried out by
immunohistochemical staining of the lung. Tumours from both
mouse genotypes were positive for TTF-1 and surfactant protein
C, implying that they are adenocarcinomas (Supplementary
Fig. 4b). KT tumours had significantly increased cellular
proliferation compared with K-RasG12D tumours, as judged by
quantification of Ki67-positive cells (Fig. 5f,g). Quantification of
the percentage of c-Jun-positive cells per tumour showed a mild
but significant increase in KT mice compared with K-RasG12D
mice (Fig. 5h,i). Taken together, these data demonstrate that
Trim7 cooperates with oncogenic Ras in lung adenocarcinoma
formation.
0
10
20
R2
6T
rim
7
K-R
as
G1
2D KT
***
H&E
TTF1
K-RasG12D KT
K-Ras
GFPStopR26
Conditional K-RasG12D expression
K-RasG12DStop
Trim7
KT
Conditional Trim7 overexpression
    + GFP labelling
+ Adeno-Cre i.t.
Relative Trim7 
transgene expression 
0
20
40
60
80
%
 K
i6
7 
po
sit
ive
 c
el
ls
K-
Ra
sG
12
D
KT
0
20
40
60
80
%
 c
-J
un
 p
os
itiv
e 
ce
lls
K-
Ra
sG
12
D
KT
***
*
Ki67
c-Jun
K-RasG12D KT
K-RasG12D KT
Actin
RACO-1
K-RasG12D KT
Tumour1 2 3 1 2 3
IRES
K-RasG12D
KT
0 105 15
%
 T
TF
-1
-p
os
itiv
e 
ar
ea
Figure 5 | RACO-1 and Trim7 cooperate with K-RasG12D to drive lung tumorigenesis. (a) Scheme of KTmouse model. i.t., intratracheal. (b) Quantitative
PCR showing expression of the Trim7 transgene in KTmouse lung tissue. Error bars indicate s.d. n¼ 3 tumours per genotype. (c) Western blot showing
RACO-1 protein levels in KTmouse lung tissue. (d) Haematoxylin and eosin (H&E) stain and TTF-1 immunohistochemistry on whole-lung sections from KT
and K-RasG12D mice 12 weeks after Cre induction ( 1.25 magnification). Scale bar, 2mm. (e) Quantification of the percentage of total lung area stained
with TTF-1 in mice of the indicated genotypes. Each data point represents a whole-lung section from one mouse. n¼ 5 R26Trim7, 9 K-RasG12D and 12 KT
mice. (f,g) Staining (40 magnification; f) and quantification (g) of Ki67-positive cells in lung tumours from mice of the indicated genotypes. Each data
point represents one tumour. All tumours from one lung section per mouse were analysed (five mice per genotype). n¼ 36K-RasG12D and 243KT tumours.
(h,i) Staining (40 magnification; h) and quantification (i) of c-Jun-positive cells in lung tumours from mice of the indicated genotypes. Each data point
represents one tumour. All tumours from one lung section per mouse were analysed (five mice per genotype). n¼43 K-RasG12D and 151 KT tumours.
*P¼0.02, ***Po0.001 (Student’s t-test). Error bars in e,g,i indicate mean±s.e.m. Scale bars in f,h, 100mm.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7782 ARTICLE
NATURE COMMUNICATIONS | 6:6782 | DOI: 10.1038/ncomms7782 | www.nature.com/naturecommunications 7
& 2015 Macmillan Publishers Limited. All rights reserved.
Trim7 depletion restrains tumour cell proliferation. RACO-1
acts as a transcriptional co-activator of c-Jun and reduced RACO-
1 level leads to a reduction in c-Jun transcriptional activity15,16. A
luciferase assay using a stably integrated chromosomal AP-1
reporter construct (collagenase–luciferase) showed a similar
decrease in gene expression when either Trim7 or RACO-1
were depleted with shRNA, consistent with Trim7 regulating the
transcription of c-Jun/AP-1 target genes via RACO-1 (Fig. 6a).
In human lung adenocarcinoma, oncogenic Ras mutations are
frequently associated with mutations in other tumour suppressors
such as p53 (ref. 30). Therefore, to test the effects of Trim7
depletion, we used primary murine lung adenocarcinoma cells
derived from a K-RasG12D; p53DL/DL (KP) mouse line, which
closely resembles human lung adenocarcinoma (Supplementary
Fig. 5a). We generated KP cells stably expressing two different
shRNAs against Trim7. Trim7 depletion suppressed the prolif-
eration of KP cells, and the reduction in proliferation correlated
with the extent of Trim7 knockdown in the two cell lines
(Supplementary Fig. 5b,c). Trim7 depletion in KP cells with the
most efficient knockdown construct (shTrim7-2) resulted in a
reduced level of RACO-1 (Supplementary Fig. 5d) and quanti-
tative RT–PCR analysis revealed that c-Jun target genes were
downregulated in Trim7 knockdown cells (Supplementary
Fig. 5e), supporting the observation that Trim7 regulates c-Jun
transactivation function and cellular proliferation. To test the
in vivo effect of Trim7 knockdown on KP cells, we subcuta-
neously injected shControl cells in the left flank and shTrim7-2
cells in the right flank of NOD-SCID mice. Trim7 knockdown
resulted in significantly smaller xenograft tumours after 20 days
(Supplementary Fig. 5f,g).
To further test the effect of Trim7 depletion in a clinically
relevant scenario, we decided to knock down Trim7 in an already
established tumour. To achieve this we generated H727 cell lines
expressing a doxycycline-inducible shTrim7 or shControl con-
struct (Fig. 6b). We first measured the proliferation of these cell
lines in vitro. Cells were plated and allowed to grow for 36 h
without doxycycline, at which stage the proliferation of both cell
lines was comparable. After 36 h, cells were treated with
2 mgml 1 doxycycline and their proliferation was monitored
for a further 120 h period. On doxycycline treatment, shTrim7-
expressing cells showed a significant decrease in proliferation
(Fig. 6c).
Next, we carried out a xenograft experiment with these cell
lines. After subcutaneous injection of untreated shControl and
shTrim7 cells into NOD-SCID mice as before, xenografts were
allowed to grow to a palpable tumour mass, and then mice were
given doxycycline every day to induce and maintain the
expression of the shRNA. In control mice that did not receive
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doxycycline treatment, tumours grew equally (Fig. 6d,e). In the
cohort that received doxycycline treatment, shTrim7-expressing
tumours grew significantly slower than the control tumours
(Fig. 6d,e). This experiment demonstrates that depletion of Trim7
in an established tumour can slow tumour cell proliferation. We
conclude that Trim7 functions to stabilize RACO-1 and stimulate
c-Jun-mediated gene expression and cellular proliferation, and is
required for efficient tumour growth driven by oncogenic Ras.
Discussion
More than 25 years ago AP-1 was identified as an activity that
bound to DNA elements in the promoters of the metallothionein
and collagenase genes31,32. The tumour promoter TPA
dramatically increases transcription of these genes in an AP-1-
dependent manner. The classical Jun/Fos AP-1-binding site,
TGACTCA, was identified as the element that mediates TPA
induction of the metallothionein and collagenase genes, and is
therefore known as the TPA response element. TPA strongly
activates the MEK/ERK MAP kinase pathway, but is only a weak
activator of JNK signalling and c-Jun N-terminal
phosphorylation33. However, while JNK-mediated c-Jun
phosphorylation is a well-established means of stimulating
c-Jun/AP-1 activity, the precise molecular connection between
c-Jun and growth factor signalling that is independent of
N-terminal phosphorylation has been enigmatic.
Our previous work demonstrated that RACO-1 functions as a
molecular link between Ras signalling and c-Jun activity15.
RACO-1 acts as a transcriptional co-activator of c-Jun and
stimulates expression of target genes required for cellular
proliferation, such as cyclinD1, cdc2 and hb–egf. RACO-1
stability plays a central role in the regulation of Ras-c-Jun
crosstalk. On activation of growth factor signalling, the
ubiquitination of RACO-1 shifts from degradative K48-linked
autoubiquitination to a nondegradative K63-linked
ubiquitination, thereby increasing RACO-1 protein levels and
AP-1 activity. In addition, PRMT1-mediated methylation is
required for RACO-1 to form a stable dimer, which is responsive
to MEK–ERK signalling and can interact with c-Jun. Here we
have identified the E3 ubiquitin ligase Trim7 as another
important regulator of Ras-c-Jun crosstalk, responsible for
MEK-driven stabilization of RACO-1 (Fig. 7).
Trim family proteins are involved in a broad range of biological
processes, and their alterations are associated with diverse
pathological conditions, such as developmental disorders, neuro-
degenerative diseases, viral infections and cancer34–36. Trim7 was
first identified as glycogenin interacting protein and shown to be
important in glycogen biosynthesis37. Although ubiquitin ligase
activity has been predicted for Trim7 because of the presence of
the RING domain, no experimental validation has been carried
out. Our data suggest that Trim7 has ubiquitin ligase activity
towards RACO-1. On MEK–ERK activation, the ERK
downstream kinase MSK1 is activated through phosphorylation,
and active MSK1 phosphorylates Trim7, thereby stimulating its
activity towards RACO-1. As with many other enzymes,
activation by phosphorylation is common among E3 ubiquitin
ligases; for example, the regulation of c-Jun turnover through
JNK-dependent phosphorylation of the E3 ligase Itch38,39.
The crosstalk between different post-translational modi-
fications has become a recurring theme in biology40, and
many signalling pathways, including the Ras–Raf–MEK–ERK
pathway, are subject to multiple protein modifications
including farnesylation3, phosphorylation3, ubiquitination41,42,
sumoylation43 and methylation 44,45, among others. This enables
the pathway to be responsive to different signal inputs with
tighter multilayered regulation. Our study adds to the growing
body of data showing that phosphorylation and ubiquitination
not only cooperate via priming or competing modifications on
the same protein, but also contribute as integral components of
signal transmission cascades40,41,46.
A significant amount of research has been carried out to
develop inhibitors of the Ras signalling pathway for therapeutic
intervention in human malignancies. It is becoming increasingly
apparent that monotherapy targeting a single kinase is only
transiently effective, as the cells become resistant to the inhibitor
via various mechanisms, as in the case of the B-Raf inhibitor
vemurafenib47–51. Combined inhibition of B-Raf and MEK has
shown promising results and has now been approved for
treatment of B-Raf-V600E metastatic melanoma. However, the
long-term efficacy of this treatment has been limited by
emergence of resistance through mutation in MEK and copy
number gain in B-RAF-V600E (ref. 52). Targeting effectors
downstream of ERK is a promising approach, which could
improve efficacy and reduce toxicity53,54. Our data show that
knocking down Trim7 in primary KP lung tumour cells reduced
cell proliferation, and significantly decreased tumour growth in
xenograft experiments. Moreover, depletion of Trim7 in an
established xenograft tumour also reduced tumour growth,
supporting the idea that therapeutic intervention in the MSK1/
Trim7/RACO-1 signalling pathway is potentially promising.
Methods
Cell lines and antibodies. Human embryonic kidney (HEK) 293T cells, human
lung adenocarcinoma H727 cells and primary murine lung adenocarcinoma cells
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum. HEK293T and H727 cells were obtained from Cancer
Research UK Cell Services. Polyclonal RACO-1 (HPA030098) and Trim7
(HPA039213) antibodies were from Sigma. Antibodies against p-ERK1/2 (9106),
total ERK1/2 (9102), pCREB (9191), total CREB (9197), MSK1 (3489) and MSK2
(3679) were from Cell Signaling Technology; Jun (610326) from BD Transduction
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Figure 7 | Schematic model of the pathway linking Ras with c-Jun/AP-1.
A phosphorylation/ubiquitination cascade via MSK1, Trim7 and RACO-1
links growth factor signalling to c-Jun/AP-1 activation.
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Laboratories; Flag (A8592) and HA (haemagglutinin; H 6908) from Sigma; b-actin
(ab49900), GFP (ab290) from Abcam; and GST (sc-459) from Santa Cruz. Mouse
monoclonal antibody against Myc tag was generated in-house. Anti-FLAG
horseradish peroxidase (HRP) antibody was used at 1:5,000 dilution and anti-b-
actin HRP antibody was used at 1:30,000 dilution. All other antibodies were used at
1:1,000 dilution for western blots. Uncropped scans of western blots are shown in
Supplementary Fig. 6.
cDNA constructs and transfections. RACO-1 cDNA was cloned in BamHI–
EcoRI sites of pCMV2B to generate FLAG–RACO-1, and in HindIII–BamHI sites
of pEGFP(C3) to generate GFP–RACO-1. Deletion mutants and point mutants of
RACO-1 were generated in the FLAG–RACO-1 construct and verified by
sequencing15. Human Trim7 isoform 1 cDNA in pDONR vector (Invitrogen) was
obtained from Genecopoeia and transferred to N-terminal Myc and GST-tagged
pDEST vector (Invitrogen) by LR recombination, as per the manufacturer’s
instructions. Site-directed mutagenesis of Trim7 was carried out on Trim7/pDONR
and then moved to Myc- or GST-tagged pDEST vector by LR recombination. His-
tagged ubiquitin K48R and ubiquitin K63R constructs were a gift from Andreas
Hock (University of Marburg, Germany), and MEK1R4F was a gift from Melanie
Cobb (The University of Texas Southwestern Medical Center). Flag-tagged MSK1,
MSK1 D565A and GST-tagged CREB were obtained from the MRC Protein
Phosphorylation and Ubiquitylation Unit, Dundee. All mutagenic constructs
generated were confirmed by sequence analysis. HEK293T and H727 cells were
transfected with polyethyleneimine.
RNA interference constructs and Lentivirus production. siRNA sequences for
human Trim7, MSK1 and MSK2 knockdown were designed using Dharmacon
siDESIGN centre. Oligonucleotide sequences (sense strand) were: siTrim7 (1):
50-CGGAAAAGAAGGAGAGCAA-30 ; siTrim7 30 untranslated repeat (2): 50-GCA
UCACGGCUCUCCAGCA-30 ; siMSK1 (1): 50-GCAGAAGAGUUCACAGAAA-30 ;
siMSK1 (2): 50-GGAAAUAACAGCUCUGAAA-30 ; siMSK2 (1): 50-CGGCCGAGA
UCAUGUGCAA-30; siMSK2 (2): 50-GCCGAGAUCAUGUGCAAAA-30 . RISC free
siRNA from Dharmacon was used as a control. shRNA sequence for human
RACO-1 (50-tgTGATGGACCGTAGGAAGAAttcaagagaTTCTTCCTACGGTCCA
TCAttttttc-30) was cloned into the IRES-GFP lentiviral construct pLentiLox 3.7
(ref. 16). shRNA for human c-Jun (SHCLND-NM_002228) and non-targeting
shRNA (SHC016) were obtained from Sigma. siTrim7(1) was cloned into
pLentiLox 3.7. Hairpin sequence (shown in upper case characters) was: shTrim7-
50-tgCGGAAAAGAAGGAGAGCAAttcaagagaTTGCTCTCCTTCTTTTCCGtt
ttttc-30 . shRNA against luciferase (50-tgCGTACGCGGAATACTTCGAttcaagaga
TCGAAGTATTCCGCGTACGttttttc-30) was cloned in pLentiLox 3.7 and used as a
control. GIPZ shRNA constructs for mouse Trim7 (shTrim7-1, clone
V3LMM_428696: 50-GAACTTCTTCAGCAATCCT-30 and shTrim7-2, clone
V3LMM_428699: 50-TGTTGAGTTGCATTGCCCA-30) and TRIPZ Dox-inducible
shRNA constructs for human Trim7 (shTrim7, clone V3THS_351926: 50-TGAGC
TGTCTCCTGGATCT-30) were obtained from Thermo Scientific. For lentiviral
production, low-passage HEK293T was transfected with the respective shRNA
construct and the accessory plasmids VSV-G and D8.2 using polyethyleneimine.
After 48 h, medium containing the infectious virus was centrifuged, filter-sterilized,
supplemented with 8 mgml 1 polybrene and used to infect KP or H727 cells for
48 h. Cells were allowed to recover for another 48 h before adding puromycin
for selection of cells stably expressing the shRNA. Puromycin-resistant cells
were further sorted for high GFP (in the case of GIPZ constructs) or high red
fluorescent protein (RFP) (in the case of TRIPZ constructs) expression using flow
cytometry.
Reporter assay. Stable HeLa clones bearing an array of amplified Collagenase–
Luciferase gene units were obtained by blasticidin selection after co-transfection of
equimolar amounts of  517/þ 63 Collagenase-Luc55,56 and pDBN-AR1, which
promotes an amplification of co-transfected plasmids57. Cells were plated in 24
wells and transfected with 250 ng shRNA constructs with 50 ng Ubiquitin-Renilla
as an internal control. After 48 h the cells were lysed and luciferase activity was
measured using the Dual Luciferase reporter assay (Promega), as per the
manufacturer’s instructions.
qRT–PCR on cell lines. RNA was extracted from cells using the Qiagen RNAeasy
mini kit, DNase-treated (Ambion) and cDNA-synthesised using Superscript III
(Invitrogen) according to the manufacturer’s instructions. QPCR was performed
using a ABIPrism 7500HT sequence detection system with SYBR Green
incorporation. QPCR primers were as follows: mouse Trim7, forward: 50-cagctcaa
ctgtgggcact-30 , reverse: 50-gcatgtcctccactgcatag-30 ; mouse c-Jun, forward: 50-tgaaag
ctgtgtcccctgtc-30 , reverse: 50-atcacagcacatgccacttc-30 ; mouse cyclin D1, forward:
50-gtgcgtgcagaaggagattgt-30, reverse: 50-ctcacagacctccagcatcca-30 ; mouse HB–EGF,
forward: 50-tgctgccgtcggtgatg-30 , reverse: 50-caccaacgcggacaacact-30; mouse cdc2,
forward: 50-ggacgagaacggcttggat-30, reverse: 50-attcgtttggcaggatcatagac-30 ; mouse
CD44, forward: 50-ctcctggcactggctctga-30, reverse: 50-ctgcccacaccttctcctactatt-30 ;
mouse b-actin, forward: 50-atgctccccgggctgtat-30 , reverse: 50-cataggagtccttctgacc
cattc-30 , human Trim7, forward: 50-ttctccagcttctgggtagc-30 , reverse: 50-cgctgag-
cagggagtagc-30 ; human c-Jun, forward: 50-ccaaaggatagtgcgatgttt-30 , reverse: 50-ctgtc
cctctccactgcaac-30 ; human CyclinD1, forward: 50-agctcctgtgctgcgaagtggaaac-30 ,
reverse: 50-agtgttcaatgaaatcgtgcggggt-30 ; human cdc2, forward: 50-tggatctgaagaaatac
ttggattcta-30 , reverse: 50-caatcccctgtaggatttgg-30 ; human CD44, forward: 50-tgccgctt
tgcaggtgat-30 , reverse: 50-ggcctccgtccgagaga-30 ; human MSK1, forward: 50-tgctgacag
attttggtctga-30 , reverse: 50-atagttccacaaaaggaatatgctc-30 ; human MSK2, forward:
50-cacgaggtgcatcacgac-30, reverse: 50-gctgaagtgccgcttctt-30 ; human Actin, forward:
50-tggatcagcaagcaggagtat-30 , reverse: 50-gcatttgcggtggacgat-30 . All primer pairs
generated a single PCR product, as determined by dissociation curve analysis.
Immunoprecipitations. HEK293T cells expressing Myc–Trim7 with or without
FLAG–RACO-1 were lysed with Buffer A (0.2% NP-40, 150mM NaCl, 20mM Tris
pH 7.5, 500 mM EDTA, protease inhibitor cocktail (Sigma), 100mM phenylmethyl
sulphonyl fluoride (PMSF), 1mM Na3VO4, 50mM NaF, 1mM b-glycerophosphate
and 1mM dithiothreitol (DTT)) and subjected to Flag immunoprecipitation
with anti-Flag agarose beads (A2220, Sigma). For coimmunoprecipitation of
GFP–RACO-1 with Myc–Trim7, 293T cells expressing Myc–Trim7 and WT or
deletion mutant GFP–RACO-1 were lysed in buffer A and then subjected to Myc
immunoprecipitation with anti-Myc agarose beads (A7470, Sigma).
In vivo and in vitro ubiquitination assays. For in vivo ubiquitination assays, His–
Ubiquitin was affinity-purified with Ni2þ -NTA agarose beads58. Briefly, FLAG–
RACO-1 and His–Ubiquitin with or without Myc–Trim7 were transfected in 293T
cells. Cells were lysed in buffer B (100mM sodium phosphate pH 8.0, 5M
guanidinium hydrochloride) containing 10mM imidazole. Ubiquitinated proteins
were precipitated using Ni2þ -NTA agarose beads (Qiagen). Beads were washed
three times in buffer B containing 20mM imidazole, and then three times in buffer
containing 1M guanidinium hydrochloride and finally three times in buffer C
(25mM Tris pH 6.5, 20mM imidazole). Proteins were eluted from the beads by
addition of 250mM imidazole and were subjected to western blotting.
For in vitro ubiquitination, FLAG–RACO-1 was immunoprecipitated from
Trim7-depleted HEK293T cells using anti-FLAGM2 agarose beads (Sigma), washed
with buffer A containing 1M NaCl, and then with buffer A containing no NaCl and
finally with buffer A containing 150mM NaCl. Immunoprecipitated protein was
eluted with 100ngml 1 3X-FLAG peptide (Sigma). Eluted FLAG–RACO-1 was
incubated with 50 nM UBE1, 500 nM UbcH5a, 5 mM HA–Ubiquitin and GST–
Trim7 wt or mutants in buffer E (50mM Tris-Cl pH 8.0, 10mMMgCl2, 2mM DTT
and 4mM ATP) for 2 h at 30 C. Reactions were stopped by addition of SDS loading
dye and subjected to western blotting with RACO-1 antibody as above.
Protein purification. GST–Trim7 wt or mutant expression vectors were trans-
formed into BL21 (DE3) bacteria and a single colony expanded. Cultures were
grown to an optical density of 0.6 and protein expression was induced by the
addition of 1mM isopropyl-b-D-thiogalactoside for 4 h at 37 C. Pelleted bacteria
were lysed by sonication in Buffer D (20mM Tris pH 7.5, 150mM NaCl, 0.5%
Triton X-100, 100 mM PMSF, 5mM b-mercaptoethanol and 10% glycerol). Fusion
proteins were isolated by affinity purification using Glutathione Sepharose 4B
beads (Amersham), washed four times with Buffer D containing 2mM glutathione
and then the protein was eluted by 20mM glutathione. Purified protein was dia-
lysed against buffer D to remove glutathione before storage.
The construct encoding the mouse C-terminal activation domain of Elk-1
(GST-(His)6-Elk-1 residues 309–429) was inserted into the BamHI–NotI cloning
sites of pET-41a (ref. 59) and expressed in Escherichia coli strain BL21(DE3;
Novagen) as an N-terminal GST-(His)6 fusion protein. For the purification of the
bacterially expressed GST-(His)6-Elk-1 309–429 construct, cells were lysed in
buffer E (50mM Tris pH 8.0, 300mM NaCl and 5mM DTT) with complete
protease inhibitor cocktail (Roche Diagnostics). The cleared lysate was applied to
glutathione sepharose resin (GE Healthcare Life Sciences), washed extensively first
with buffer E and finally with buffer F (50mM Tris pH 8.0, 150mM NaCl and
5mM DTT). The GST-(His)6 tag was cleaved overnight by incubating the protein
with 1:50 (w/w) GST-3C protease on the resin. Cleaved protein was collected and
further purified on a Superdex 75 HR10/30 size exclusion column (GE Healthcare
Life Sciences) in buffer G (25mM Tris pH 7.5, 150mM NaCl).
Constitutively active ERK2 was expressed in bacteria as an N-terminal (His)6
fusion protein and purified using the protocol described in ref. 60. Briefly,
expression of recombinant ERK2 was induced with 0.25mM isopropyl-b-D-
thiogalactopyranoside at 30 C for 12–14 h. Cells were lysed in buffer H (50mM
sodium phosphate, pH 8.0, 0.3M NaCl) with complete protease inhibitor cocktail
(Roche Diagnostics). The lysate was clarified at 20,000g for 30min at 4 C. The
resulting supernatant was applied to Ni2þ -NTA resin equilibrated in buffer H,
washed with 20 volumes of buffer I (20mM Tris-HCl, pH 8.0, 0.3M NaCl and
10mM imidazole) and eluted with 0.25M imidazole, pH 7.0, in buffer I. Eluted
protein was dialysed overnight against buffer J (20mM Tris-HCl, pH 7.5, 50mM
NaCl, 1mM DTT and 1mM EGTA), applied to a Mono Q column (GE
Healthcare) equilibrated in the same buffer and eluted with 500mM NaCl in buffer
I. Fractions containing purified ERK2 were pooled, dialysed against buffer I
containing 20% glycerol and protease inhibitors, frozen in liquid nitrogen and
stored at  80 C in small aliquots.
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In vitro kinase assay. For ERK kinase activity, GST or GST–Trim7 or Elk-1 was
incubated with ERK2 in buffer K (50mM Tris-Cl pH 8.0, 150mM NaCl, 10mM
MgCl2, 1mM EDTA and 2mM DTT) containing 0.2mM ATP and 20 mCi g32P
ATP for 1 h at 30 C. The reaction was stopped by adding SDS loading dye and
analysed on SDS–PAGE. The gel was dried and bands were visualized with
autoradiography.
For MSK1 kinase reaction, FLAG–MSK1 WT or FLAG–MSK1 D565A were
ectopically expressed in 293T cells, immunoprecipitated by anti-FLAG M2 agarose
beads (Sigma), washed and eluted using 100mgml 1 3 FLAG peptide (Sigma).
Eluted MSK1 or MSK1 D565A was incubated with GST–Trim7 or GST–CREB in
buffer H containing 20mM ATP and 20 mCi g32P ATP for 1 h at 30 C. The
reactions were analysed as described above.
Ethical considerations. Experiments using mice (Mus musculus) were carried out
with the approval of the London Research Institute’s Ethical Review Committee
according to the UK Animals (Scientific Procedures) Act 1986. For the lung cancer
model, animals were culled 12 weeks after intubation, before tumours outwardly
affect the health of the animal. For xenograft experiments, subcutaneous tumours
were allowed to reach a maximum of 1.4 cm in length before the experiment was
terminated.
Generation of transgenic mice. The conditional ROSA26-Trim7-IRES-eGFP-
pAþ targeting vector (using human cDNA sequence for Trim7 isoform 1) was
generated through LR reactions between the pDONR-Trim7 and the Gateway
compatible pROSA26-DV1 plasmids61. The ROSA26-Trim7 conditional targeting
vector was linearized with Pvu1 and electroporated into the G4 ES cell line62, and
ES clones were selected by G418 resistance and screened by PCR analysis61.
Correctly targeted ROSA26-Trim7 ES cell clones were aggregated with WT Swiss
diploid host embryos and strong male chimeras were generated that transmitted
the conditional ROSA26-Trim7-IRES-eGFP-pAþ transgene to F1 generation
offspring61. These mice were then bred with the K-RasG12D mouse model26,27 to
generate KT mice.
Adenoviral infection. Adeno-Cre virus (Ad5CMVCre) was purchased from the
Gene Transfer Vector Core, University of Iowa. Intratracheal intubation26 was
carried out on animals at 8–12 weeks of age using a dose of 2.5 107 viral particles
per mouse. Briefly, the adenovirus was prepared in MEM and 10mM calcium
chloride was added and allowed to precipitate at room temperature. The mouse
was anaesthetized and the virus preparation was administered via a catheter
inserted into the trachea. Both male and female transgenic mice were used. A
sample size of at least five mice per genotype was used to allow statistical analysis to
be performed, with no sample exclusion criteria. Mice were culled 12 weeks after
intubation for analysis.
Immunohistochemistry and qRT–PCR on transgenic mouse tissue. Mice were
killed by cervical dislocation and lungs were perfused with PBS and then with 10%
neutral buffered formalin (NBF). Lung tissue was incubated in 10% NBF overnight
and washed with 70% ethanol. Paraffin-embedded 4-mM sections were stained with
the following antibodies: TTF-1 (ab40880, Abcam), GFP (ab290, Abcam), Sur-
factant Protein C (AB3786, Millipore), c-Jun (610326, BD Biosciences) and Ki67
(M7248, DAKO). All the antibodies were used at 1:100 dilution for immunohis-
tochemistry. TTF-1 was used as a marker of lung adenocarcinoma to differentiate
transformed from untransformed lung tissue. The ImageJ software was used to
quantify the TTF-1-positive transformed lung area. Lungs from 5 R26Trim7,
9K-RasG12D and 12 KT mice were analysed. Each data point in Fig. 5e represents
one mouse.
For Ki67 or c-Jun staining, the entire lung section was imaged using a
Nanozoomer (Hamamatsu) slide scanner. The tumour areas were outlined and
Ki67- or c-Jun-positive and -negative nuclei were quantified automatically with the
APPsolute Digital Pathology software (VisioPharm) using a standard threshold
staining intensity. For each tumour, the number of Ki67- or c-Jun-positive cells was
calculated and represented as percentage of total number of cells. Five mice of each
genotype were used; in total, 36 K-RasG12D and 243 KT tumours were analysed for
Ki67 staining and 43 K-RasG12D and 151 KT tumours were analysed for c-Jun
staining. Each data point in Fig. 5g,i represents one tumour.
For RNA and protein isolation, lungs were perfused with PBS and minced and
then resuspended in DMEM containing collagenase type III and incubated for
30min at 37 C in a shaking incubator. Cells were centrifuged for 5min at 300g and
then passed through a 70-mm cell strainer and then used for either protein
preparation or RNA isolation as described above.
Xenograft experiments. Female NOD-SCID mice were subcutaneously injected
at 8 weeks of age with shControl cells (stably transfected with shRNA construct as
described above) on the left flank and shTrim7 cells on the right. A sample size of
at least four mice per cohort was used to allow statistical analysis to be performed,
with no sample exclusion criteria. For the ‘þDox’ cohort, five mice received a daily
dose of 5mgml 1 aqueous solution of doxycycline by oral gavage starting from
day 25 and continuing to the end of the experiment. For the ‘no Dox’ cohort, four
mice did not receive any treatment as a control. Randomization and blinding were
not used. Subcutaneous tumour volumes were determined every 2 days by mea-
suring the external dimensions of the tumour with calipers. Two perpendicular
diameters were measured in each case and the longer designated ‘length’ (L) and
the shorter ‘width’ (W). The tumour volume (V) was calculated using the following
equation, taken from ref. 63:
V ¼ W2L =2
The experiment was terminated once the largest xenograft tumour reached
1.4 cm in length, whereupon the mice were culled and the tumours excised and
photographed.
Mass spectrometry. Biotinylated RACO-1(163–235) and scrambled peptides
(2mg) were incubated with Dynabeads M280 streptavidin in PBS at 4 C overnight.
Peptide-bound beads were washed and resuspended in buffer A. HeLa cells were
lysed in buffer A and then incubated with Dynabead-bound peptides for 2 h at
4 C. The beads were washed three times with buffer A containing 300mM NaCl.
For LC-tandem mass spectrometry (MS-MS), polyacrylamide gel slices (1–2mm)
containing the purified proteins were prepared for analysis using the Janus liquid
handling system (Perkin Elmer, UK). Briefly, the excised protein gel pieces were
placed in wells of a 96-well microtiter plate, destained with 50% (vol/vol) acet-
onitrile and 50mM ammonium bicarbonate, reduced with 10mM DTT and
alkylated with 55mM iodoacetamide. Alkylated proteins were digested with
6 ngml 1 trypsin (Promega, UK) overnight at 37 C. The resulting peptides were
extracted in 1% (vol/vol) formic acid, 2% (vol/vol) acetonitrile and were analysed
by nanoscale capillary LC-MS-MS using a nanoAcquity UPLC (Waters, UK) to
deliver a flow of 300 nlmin 1. A C18 Symmetry 5-mm, 180-mm by 20-mm m-
precolumn (Waters) trapped the peptides before separation on a C18 BEH130 1.7-
mm, 75-mm by 250-mm analytical UPLC column (Waters). The peptides were
eluted with a gradient of acetonitrile. The analytical column outlet was interfaced
with a Triversa NanoMate microfluidic chip for mass spectrometric analysis
(Advion, UK). Mass spectrometric information was obtained using an orthogonal-
acceleration quadrupole-time of flight mass spectrometer (Synapt HDMS; Waters).
Data-dependent analysis was carried out, for which automatic MS-MS data on the
eight most intense, multiply charged precursor ions in the m/z range of 400–1,500
were acquired. MS-MS data were acquired over the m/z range of 50–1,995. LC-MS-
MS data were then searched against the UniProt KB (release 15.5) protein database
using the Mascot search engine programme (Matrix Science, UK)64.
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